The PROTEUS Consortium is funded by unrestricted support from Pfizer Inc., who had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. M.C. receives funding from the National Institute for Health and Care Research (NIHR), UKRI, NIHR Biomedical Research Centre, NIHR Applied Research Collaboration West Midlands, NIHR Birmingham–Oxford Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, GSK and Merck, and has received personal fees from Aparito, CIS Oncology, Halfloop, Merck, Pfizer, Vertex and Gilead outside the submitted work. A.M.S. has, in the past two years, received related funding from Pfizer Global and unrelated funding from UroGen Pharma Ltd, Sivan Innovation, Hematology/Oncology Pharmacy Foundation, Cancer and Aging Research Group (CARG) Infrastructure grants (R21AG059206 and R33AG059206), and the American Society of Clinical Oncology, and was a paid consultant with Navigating Cancer in 2021. C.S. has consulting funding from Shionogi. N.C. has unrelated consulting support from Boehringer Ingelheim.